Ivabradina Teva Italia (Ivabradine)

Ivabradine works by selectively blocking the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. This reduces the slope of diastolic depolarisation, slowing the heart’s intrinsic pacing and lowering heart rate without diminishing myocardial contractility or blood pressure.

The dosage of Ivabradina Teva Italia is determined by the prescribing clinician based on the individual’s clinical condition, heart‑rate response, and tolerability. The prescriber will set the appropriate dose and titration schedule according to current therapeutic guidelines.

Safety of ivabradine during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

The primary alternative for heart‑rate control in angina and heart failure is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting beta‑adrenergic receptors, which can be advantageous in patients who cannot tolerate beta‑blockers due to bronchospasm, severe asthma, or peripheral vascular disease.

Ivabradina Teva Italia should be stored at ambient temperature below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

The medication is administered orally, usually as a tablet taken with or without food. The exact timing and frequency are prescribed by the treating physician, who will also advise on any necessary adjustments based on heart‑rate monitoring.

Serious risks include severe bradycardia, symptomatic sinus pauses, atrial fibrillation, and marked hypotension. Patients should be educated to report symptoms such as dizziness, fainting, palpitations, or visual disturbances promptly to their healthcare provider.

Ivabradina Teva Italia is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of the tablet’s excipients.